Cancer combo therapy under the microscope: real-world study launched

NCT ID NCT07665736

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a strict lab setting. The goal is to gather practical evidence on effectiveness and safety to help doctors make better treatment choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
immune checkpoint inhibitors combined with radiotherapy
What this could lead to
If successful, this study could provide real-world evidence to guide better treatment decisions for cancer patients using immunotherapy and radiotherapy together.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary widely due to the diverse patient population and treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITORS (ICIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.